Crowdonomics
WatchlistPortfolio
All companies
CALVIRI logo

CALVIRI

Operating

Calviri, Inc.

Healthcare · Founded 2015

Visit website

Let's end cancer - first in dogs, then people

Post-money valuation ⓘ
$165.9M
As of Oct 2024 · from Reg CF Offering (2024) · pre-money + amount raised, not a traded price
Total raised
$20,451,716
Crowd $0 · Private $20.5M · 8 rounds since 2018
Latest share price
$3.22
Rule 506(b) · Common Stock · Sep 2023 offering price

Financials

FY2022–FY2023 · from SEC filings · hover any figure for its source
$45K
−$5.5M
2022
$22K
−$5.5M
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022 reviewed
FY2023 reviewed
Income statement
Revenue
$44,550
$21,661
Cost of goods sold
$0
$0
Gross margin
100%
100%
Net income
-$5,530,006
-$5,540,651
Taxes paid
$0
$0
Balance sheet
Cash
$1,229,944
$349,758
Accounts receivable
$0
$100,000
Total assets
$1,783,470
$918,413
Short-term debt
$215,726
$294,581
Long-term debt
$0
$0
Total liabilities
$215,726
$294,581
Other
Headcount
—
24

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$165.8M
pre-money
Reg CF · Common · Aug 2024

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

$3.22$1.61$1.81
Nov 2021Sep 2023
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Fundraising history

Rule 506(b) · Equity · Oct 2024Closed
Raised $785KInvestors 10
Reg CF · Common Stock · Aug 2024Closedvia StartEngine
Raised $0 / $1.2MInvestors 40Post-money $165.9M
Rule 506(b) · Convertible Note · Sep 2024Closed
Raised $150KInvestors 1
Rule 506(b) · Common Stock · Sep 2023Closed
Raised $3.7MInvestors 3
Rule 506(b) · Equity · Oct 2021Closed
Raised $11.1MInvestors 32
Rule 506(b) · Equity · Sep 2020Closed
Raised $2.4MInvestors 5
Rule 506(b) · Equity · Sep 2020Closed
Raised $430KInvestors 3
Rule 506(b) · Convertible Note · Dec 2018Closed
Raised $1.9MInvestors 4

Team

3 people
Stephen Johnston
CEO, Director, Scientific Advisory Board Member and principal accounting officer
Kathryn Frances Sykes
Director, VP Research and Product Development
Jacque J. Sokolov
Director

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Delinquent

Filed 0 of 2 annual reports (FY2024–FY2025)

Missing: 2024, 2025

40 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

View all 11 filings on EDGAR
  • Form DNov 12, 20240001763612-24-000002
    EDGAR
  • Form C-UNov 8, 20240001665160-24-001569
    EDGAR
  • Form DSep 24, 20240001763612-24-000001
    EDGAR
  • Form CAug 21, 20240001665160-24-001204
    EDGAR
  • Form DOct 4, 20230001763612-23-000002
    EDGAR
  • Form D/AMay 9, 20230001763612-23-000001
    EDGAR
  • Form DNov 12, 20210001763612-21-000002
    EDGAR
  • Form DOct 20, 20200001763612-20-000003
    EDGAR
Source: ManualCIK 0001763612Share price $3.22

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.